The VSTM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VSTM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VSTM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View VSTM Detailed Price Forecast - CNN Money | View VSTM Detailed Summary - Google Finance | ||
View VSTM Detailed Summary - Yahoo! Finance | View VSTM Stock Research & Analysis - Zacks.com |
View VSTM Trends & Analysis - Trade-Ideas | View VSTM Major Holders - Barrons | ||
View VSTM Call Transcripts - NASDAQ | View VSTM Breaking News & Analysis - Seeking Alpha | ||
View VSTM Annual Report - CompanySpotlight.com | View VSTM OTC Short Report - OTCShortReport.com | ||
View VSTM Fundamentals - TradeKing | View VSTM SEC Filings - Bar Chart | ||
View Historical Prices for VSTM - The WSJ | View Performance/Total Return for VSTM - Morningstar | ||
View the Analyst Estimates for VSTM - MarketWatch | View the Earnings History for VSTM - CNBC | ||
View the VSTM Earnings - StockMarketWatch | View VSTM Buy or Sell Recommendations - MacroAxis | ||
View the VSTM Bullish Patterns - American Bulls | View VSTM Short Pain Metrics - ShortPainBot.com |
View VSTM Stock Mentions - StockTwits | View VSTM Stock Mentions - PennyStockTweets | ||
View VSTM Stock Mentions - Twitter | View VSTM Investment Forum News - Investor Hub | ||
View VSTM Stock Mentions - Yahoo! Message Board | View VSTM Stock Mentions - Seeking Alpha |
View Insider Transactions for VSTM - SECform4.com | View Insider Transactions for VSTM - Insider Cow | ||
View VSTM Major Holdings Summary - CNBC | View Insider Disclosure for VSTM - OTC Markets | ||
View Insider Transactions for VSTM - Yahoo! Finance | View Institutional Holdings for VSTM - NASDAQ |
View VSTM Stock Insight & Charts - FinViz.com | View VSTM Investment Charts - StockCharts.com | ||
View VSTM Stock Overview & Charts - BarChart | View VSTM User Generated Charts - Trading View |
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Posted on Thursday April 18, 2024
BOSTON, April 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Thursday April 04, 2024
BOSTON, April 04, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Posted on Monday March 18, 2024
BOSTON, March 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever global LGSOC Patient Impact Survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer (LGSOC). The results reveal a significant negative impact of LGSOC on respondents’ m
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Posted on Thursday March 14, 2024
BOSTON, March 14, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and highlighted recent progress.